Abstract
The mevalonate cascade is a key metabolic pathway that regulates a variety of cellular functions and is thereby implicated in the pathophysiology of most brain diseases, including neurodevelopmental and neurodegenerative disorders. Emerging lines of evidence suggest that statins and Rho GTPase inhibitors are efficacious and have advantageous properties in treatment of different pathologic conditions that are relevant to the central nervous system. Beyond the original role of statins in lowering cholesterol synthesis, they have anti-inflammatory, antioxidant and modulatory effects on signaling pathways. Additionally, Rho GTPase inhibitors and statins share the mevalonate pathway as a common target of their therapeutic actions. In this review, we discuss potential mechanisms through which these drugs, via their role in the mevalonate pathway, exert their neuroprotective effects in neurodegenerative and neurodevelopmental disorders.
Keywords: Cholesterol, neurodegeneration, neurodevelopment, Rho GTPase, statins.
Graphical Abstract
Current Molecular Pharmacology
Title:Mevalonate Cascade and Neurodevelopmental and Neurodegenerative Diseases: Future Targets for Therapeutic Application
Volume: 10
Author(s): Xiaodan Jiao, Niloufar Ashtari, Maryam Rahimi-Balaei, Qi Min Chen, Ilnaz Badbezanchi, Shahla Shojaei, Adel Marzban, Nima Mirzaei, Seunghyuk Chung, Teng Guan, Jiasi Li, Jerry Vriend, Shahram Ejtemaei Mehr, Jiming Kong and Hassan Marzban*
Affiliation:
- Department of Human Anatomy and Cell Science, Rm129, BMSB, 745 Bannatyne Avenue, Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, R3E 0J9,Canada
Keywords: Cholesterol, neurodegeneration, neurodevelopment, Rho GTPase, statins.
Abstract: The mevalonate cascade is a key metabolic pathway that regulates a variety of cellular functions and is thereby implicated in the pathophysiology of most brain diseases, including neurodevelopmental and neurodegenerative disorders. Emerging lines of evidence suggest that statins and Rho GTPase inhibitors are efficacious and have advantageous properties in treatment of different pathologic conditions that are relevant to the central nervous system. Beyond the original role of statins in lowering cholesterol synthesis, they have anti-inflammatory, antioxidant and modulatory effects on signaling pathways. Additionally, Rho GTPase inhibitors and statins share the mevalonate pathway as a common target of their therapeutic actions. In this review, we discuss potential mechanisms through which these drugs, via their role in the mevalonate pathway, exert their neuroprotective effects in neurodegenerative and neurodevelopmental disorders.
Export Options
About this article
Cite this article as:
Jiao Xiaodan, Ashtari Niloufar, Rahimi-Balaei Maryam, Chen Min Qi, Badbezanchi Ilnaz, Shojaei Shahla, Marzban Adel, Mirzaei Nima, Chung Seunghyuk, Guan Teng, Li Jiasi, Vriend Jerry, Mehr Ejtemaei Shahram, Kong Jiming and Marzban Hassan*, Mevalonate Cascade and Neurodevelopmental and Neurodegenerative Diseases: Future Targets for Therapeutic Application, Current Molecular Pharmacology 2017; 10 (2) . https://dx.doi.org/10.2174/1874467209666160112125446
DOI https://dx.doi.org/10.2174/1874467209666160112125446 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biochemical Markers for Brain Injury Monitoring in Children with or without Congenital Heart Diseases
CNS & Neurological Disorders - Drug Targets Carrier Mediated Systemic Delivery of Protein and Peptide Therapeutics
Current Pharmaceutical Design Targeting MET Receptor in Rhabdomyosarcoma: Rationale and Progress
Current Drug Targets Effects of Ascorbic Acid on Tax, NF-κB and MMP-9 in Human T-cell Lymphotropic Virus Type 1 Positive Malignant T-Lymphocytes
Anti-Cancer Agents in Medicinal Chemistry Role of Lipoxins and Resolvins as Anti-Inflammatory and Proresolving Mediators in Colon Cancer
Current Molecular Medicine Spin Trapping: An Essential Tool for the Study of Diseases Caused by Oxidative Stress
Current Topics in Medicinal Chemistry Comprehensive Profiling of the Low Molecular Weight Proteins and Peptides in Weak Cation Exchange Beads Human Serum Retentate
Protein & Peptide Letters Machine Learning Methods in Precision Medicine Targeting Epigenetic Diseases
Current Pharmaceutical Design IL-1 as a target in inflammation
Endocrine, Metabolic & Immune Disorders - Drug Targets Voltage-Gated Calcium Channels as Targets for the Treatment of Chronic Pain
Current Drug Targets - CNS & Neurological Disorders Natural Active Compounds from Plant Food and Chinese Herbal Medicine for Nonalcoholic Fatty Liver Disease
Current Pharmaceutical Design Recent Progress in Clinical Development of Therapeutic Antibodies Targeting Glycan-Binding Proteins
Current Drug Targets Boron Containing Macromolecules and Nanovehicles as Delivery Agents for Neutron Capture Therapy†
Anti-Cancer Agents in Medicinal Chemistry VEGF in Tumor Progression and Targeted Therapy
Current Cancer Drug Targets Gene Clusters, Molecular Evolution and Disease: A Speculation
Current Genomics Hypersensitivity Reactions to Quinolones
Current Pharmaceutical Design Targeting BMP9-Promoted Human Osteosarcoma Growth by Inactivation of Notch Signaling
Current Cancer Drug Targets Ketogenic Diets in the Treatment of Epilepsy
Current Pharmaceutical Design Hepatic Cytochrome P450 Regulation in Disease States
Current Drug Metabolism PC12 Interaction with Magnetic Nanotubes: Effects on Viability, Cell Differentiation and Cell Translocation Induced by a Magnetic Field
Current Nanoscience